RELMADA THERAPEUTICS, INC. (RLMD)

Every figure this model derived for RLMD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2014-02-28.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquireProductiveAssets 2020-12-31
cash 217,731,175 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 219,039,677 AssetsCurrent 2026-06-30
current liabilities 7,420,773 LiabilitiesCurrent 2026-06-30
equity 206,558,323 StockholdersEquity 2026-06-30
revenue 3,166 Revenues 2014-02-28
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RLMD on one particular measure came for.

RatioValue
current ratio29.52
current ratio reported29.52
revenue growth-50.61
revenue growth per share-50.61
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about RLMD's figures. Written by the derivation as it ran, not added afterwards.